A citation-based method for searching scientific literature

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135



Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James, Jill S Clancy, Joseph Chen, Jean-François Martini, Antonello Abbattista, Benjamin J Solomon. Lancet Oncol 2017
Times Cited: 363




List of shared articles



Times cited

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal, Sylvester Pawlak, Katherine Ginman, Yazdi K Pithavala. Cancer Chemother Pharmacol 2022
1

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
1

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li,[...]. Signal Transduct Target Ther 2022
1

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, E P Mitchell, J J Wright, N Takebe,[...]. NPJ Precis Oncol 2022
2


SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez. Clin Transl Oncol 2022
2


Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
0

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
0

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Ross A Soo, Eng Huat Tan, Hidetoshi Hayashi, Takashi Seto, Chia-Chi Lin, Sai-Hong Ignatius Ou, Dong-Wan Kim, Geoffrey Liu, Antonello Abbattista, Jean-François Martini,[...]. Lung Cancer 2022
0

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz. Int J Mol Sci 2022
0

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022
0

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I.
Archana Upadhya, Khushwant S Yadav, Ambikanandan Misra. Expert Opin Drug Deliv 2021
4




Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.
R Danesi, S Fogli, S Indraccolo, M Del Re, A P Dei Tos, L Leoncini, L Antonuzzo, L Bonanno, V Guarneri, A Pierini,[...]. ESMO Open 2021
7

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
9

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
2


Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma. Clin Pharmacol Ther 2021
6

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko,[...]. Transl Oncol 2021
2

Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, José Bravo Marques, Venceslau Hespanhol. Drug Saf 2021
1

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
112

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
13

A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier.
Wei Chen, Chunyu Li, Yafei Shi, Yujun Zhang, Dujia Jin, Mingyu Zhang, Mingming Bo, Guohui Li. Front Pharmacol 2021
1

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
3

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.
Joan Rou-En Choo, Ross A Soo. Expert Rev Anticancer Ther 2020
6

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Yuling Zhou, Wenjuan Jiang, Liang Zeng, Jinye Mi, Lianxi Song, Analyn Lizaso, Xinru Mao, Nong Yang, Yongchang Zhang. Lung Cancer 2020
6

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
30

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020
10

A user's guide to lorlatinib.
Misako Nagasaka, Yubin Ge, Ammar Sukari, Geetika Kukreja, Sai-Hong Ignatius Ou. Crit Rev Oncol Hematol 2020
11